GlassScriptPhysician profile
Laping Xu
NPI 1467032250
$5,593.15
in general payments reported to CMS, 2019-2025
16 companies · $2,465 in 2025
The $2,465 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.01 · 2022: $845 · 2023: $811 · 2024: $1,400 · 2025: $2,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,675.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,981.40 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,333.48 | 2022-2025 | |
| Abbvie INC. | $412.47 | 2022-2025 | |
| Vivus LLC | $401.93 | 2022-2025 | Pancreaze |
| Intra-Sana Laboratories | $236.73 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ardelyx, INC. | $217.29 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $202.18 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $160.49 | 2022 | |
| Madrigal Pharmaceuticals | $154.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Currax Pharmaceuticals LLC | $113.20 | 2024-2025 | Contrave |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $108.50 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Ironwood Pharmaceuticals, INC | $58.28 | 2024 | |
| Phathom Pharmaceuticals, INC. | $43.10 | 2024 | Voquezna |
| Novo Nordisk INC | $39.99 | 2025 | Wegovy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $18.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laping Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.